KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.

Arun J Sanyal, Kris V Kowdley, Nancy S Reau, Nikolaos T Pyrsopoulos, Christopher Allen, Zeev Heimanson, Jasmohan S Bajaj

Hepatol Commun 8(6) e0436

PMID38727685
PMCIDPMC11093560
DOI10.1097/HC9.0000000000000436
发表日期2024-05-10
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who were stratified by important baseline characteristics such as comorbid ascites or diabetes. METHODS: Pooled post hoc subgroup analysis of adults receiving rifaximin 550 mg twice daily plus lactulose or lactulose alone for 6 months in a phase 3 randomized, double-blind trial and a phase 4 open-label trial was conducted. RESULTS AND CONCLUSION: Rifaximin plus lactulose was more efficacious than lactulose alone for reducing the risk of overt HE recurrence and HE-related hospitalization in adults grouped by select baseline disease characteristics.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。